# GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM

> **NCT07314684** · PHASE4 · RECRUITING · sponsor: **Federico II University** · enrollment: 80 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)

## Interventions

- **DRUG:** semaglutide
- **DRUG:** Standard Treatment (Guideline-Based)

## Key facts

- **NCT ID:** NCT07314684
- **Lead sponsor:** Federico II University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-08
- **Primary completion:** 2027-03-08
- **Final completion:** 2027-03-08
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07314684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07314684, "GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07314684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*